Which is better, HALO or KRYS?

On the Buffett-Fit framework, Halozyme Therapeutics, Inc. (HALO) currently grades higher than KRYS — 79/100 (B grade) vs 51/100 (C). That said, "better" depends on which framework you trust — HALO wins on Warren Buffett, Benjamin Graham, Charlie Munger, and Terry Smith; KRYS wins on Philip Fisher, Peter Lynch, and Joel Greenblatt. The full pillar breakdown is on this page.

Should I buy HALO or KRYS?

This page is an educational comparison, not investment advice. Both HALO and KRYS are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is HALO better than KRYS for value investing?

On the Buffett-style value-investing framework, HALO currently grades higher — 79/100 vs 51/100, a 28-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between HALO and KRYS on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). HALO currently scores 79/100 (B grade); KRYS scores 51/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, HALO or KRYS?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. HALO and KRYS are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, HALO or KRYS?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are HALO and KRYS both Healthcare stocks?

Yes — both Halozyme Therapeutics, Inc. (HALO) and Krystal Biotech, Inc. (KRYS) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this HALO vs KRYS comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Halozyme Therapeutics

HALO$8.1BHealthcare Market cap, Sector

Krystal Biotech

KRYS$8.83BHealthcare Market cap, Sector

Overall winner

Halozyme Therapeutics

HALO 4 KRYS

Fit scores by strategy

HALO4wins

3winsKRYS

Warren Buffett

79B

D51

Benjamin Graham

83B

B74

Philip Fisher

65C

B74

Peter Lynch

53D

D58

Joel Greenblatt

40F

D59

Charlie Munger

80B

C64

Terry Smith

84B

C64

Side-by-side metrics

Metric	HALO	KRYS
Market cap	$8.1B	$8.83B Winner
P/E (TTM)	Winner: 24.0x	39.9x
EV/EBIT	Winner: 10.2x	52.9x
ROIC (TTM)

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

HALO leads on

EV/EBIT10.2xvs 52.9x+81%
ROIC (TTM)23.65%vs 13.85%+41%
P/E (TTM)24.0xvs 39.9x+40%

KRYS leads on

Debt / Equity0.0xvs 1.0x+100%

More like HALO

HALO vs PME.AX HALO vs CAMX.ST HALO vs BSLN.SW HALO vs 1681.HK

More like KRYS

KRYS vs PME.AX KRYS vs CAMX.ST

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Industries

Rankings

Glossary

Tools & Methodology

Halozyme Therapeutics

Krystal Biotech

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like HALO

More like KRYS

Related on invest-like

Key terms in this analysis